Intellia Therapeutics soars 58% after its gene-editing CRISPR therapy shows success in first human trialsBusiness Insider • 06/28/21
Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing CandidateBenzinga • 06/28/21
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) AmyloidosisGlobeNewsWire • 06/26/21
Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate SecretaryGlobeNewsWire • 06/24/21
Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell CompanyBusiness Wire • 06/22/21
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual MeetingGlobeNewsWire • 06/04/21
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
Domino's, Editas, Roblox, Teva, US Steel and More Tuesday Afternoon Analyst Calls24/7 Wall Street • 05/04/21
Analysts Estimate Intellia Therapeutics, Inc. (NTLA) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/29/21
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company UpdatesGlobeNewsWire • 04/29/21
Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual MeetingGlobeNewsWire • 04/27/21